Nuvectis Pharma stockholders re-elect directors and ratify auditor at 2024 annual meeting

Nuvectis Pharma, Inc.

Kenneth Hoberman elected Class II director with 8,026,155 votes for, 809,797 against.
Matthew Kaplan elected Class II director with 8,502,724 votes for, 333,228 against.
Ratification of Kesselman & Kesselman as auditor approved: 12,055,252 for, 31,882 against.
Voting based on 12,227,134 shares present (66.55% of outstanding) on record date April 15, 2024.
All proposals as described in definitive proxy statement filed April 29, 2024 were approved.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.